

## Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

Thomas J. Smith, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kari Bohlke, American Society of Clinical Oncology, Alexandria; Scott J. Cross, Virginia Oncology Associates, Norfolk; James L. Khatcheressian, Virginia Cancer Institute, Richmond, VA; Gary H. Lyman, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Kenneth R. Carson, Washington University, St Louis, MO; Jeffrey Crawford, Duke Medicine, Durham, NC; John M. Goldberg, University of Miami Miller School of Medicine, Miami, FL; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Cheryl L. Perkins, patient representative, Dallas, TX; George Somlo, City of Hope National Medical Center, Duarte, CA; James L. Wade, Cancer Care Specialists of Central Illinois, Decatur, IL; Antoinette J. Wozniak, Karmanos Cancer Institute, Detroit, MI; and James O. Armitage, University of Nebraska Medical Center, Omaha, NE.

Published online ahead of print at [www.jco.org](http://www.jco.org) on July 13, 2015.

T.J.S. and J.O.A. were Update Committee co-chairs.

Clinical Practice Guideline Committee approval: January 30, 2015.

Editor's note: This American Society of Clinical Oncology clinical practice guideline provides recommendations, with comprehensive review and analyses of the relevant literature for each recommendation. Additional information, including a Data Supplement with additional evidence tables, a Methodology Supplement, slide sets, clinical tools and resources, and links to patient information at [www.cancer.net](http://www.cancer.net), is available at [www.asco.org/guidelines/wbcgf](http://www.asco.org/guidelines/wbcgf).

Authors' disclosures of potential conflicts of interest are found in the article online at [www.jco.org](http://www.jco.org). Author contributions are found at the end of this article.

Corresponding author: American Society of Clinical Oncology, 2318 Mill Rd, Suite 800, Alexandria, VA 22314; e-mail: [guidelines@asco.org](mailto:guidelines@asco.org).

© 2015 by American Society of Clinical Oncology

0732-183X/15/3328w-3199w/\$20.00

DOI: 10.1200/JCO.2015.62.3488

Thomas J. Smith, Kari Bohlke, Gary H. Lyman, Kenneth R. Carson, Jeffrey Crawford, Scott J. Cross, John M. Goldberg, James L. Khatcheressian, Natasha B. Leighl, Cheryl L. Perkins, George Somlo, James L. Wade, Antoinette J. Wozniak, and James O. Armitage

### A B S T R A C T

#### Purpose

To update the 2006 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSFs).

#### Methods

The American Society of Clinical Oncology convened an Update Committee and conducted a systematic review of randomized clinical trials, meta-analyses, and systematic reviews from October 2005 through September 2014. Guideline recommendations were based on the review of the evidence by the Update Committee.

#### Results

Changes to previous recommendations include the addition of tbo-filgrastim and filgrastim-sndz, moderation of the recommendation regarding routine use of CSFs in older patients with diffuse aggressive lymphoma, and addition of recommendations against routine dose-dense chemotherapy in lymphoma and in favor of high-dose-intensity chemotherapy in urothelial cancer. The Update Committee did not address recommendations regarding use of CSFs in acute myeloid leukemia or myelodysplastic syndromes in adults.

#### Recommendations

Prophylactic use of CSFs to reduce the risk of febrile neutropenia is warranted when the risk of febrile neutropenia is approximately 20% or higher and no other equally effective and safe regimen that does not require CSFs is available. Primary prophylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on the basis of age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen. Dose-dense regimens that require CSFs should only be used within an appropriately designed clinical trial or if supported by convincing efficacy data. Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.

*J Clin Oncol* 33:3199-3212. © 2015 by American Society of Clinical Oncology

### INTRODUCTION

Neutropenia and its complications, including febrile neutropenia and infection, remain major toxicities associated with myelosuppressive systemic cancer chemotherapy.<sup>1-3</sup> In a nationwide prospective cohort study, first-cycle febrile neutropenia occurred in 6% of adults with solid tumors being treated with myelosuppressive chemotherapy.<sup>2</sup> Among patients with metastatic solid tumors, incidence of febrile neutropenia during myelosuppressive chemotherapy ranged from 13% to 21% in a large retrospective study.<sup>3</sup> Neutropenic complications require prompt evaluation and treatment with empiric antibiotics

and often require hospitalization. The risk of such complications increases in direct proportion to the severity and duration of neutropenia.<sup>4</sup> Hematopoietic colony-stimulating factors (CSFs) have been shown to reduce the duration and severity of neutropenia and the risk of febrile neutropenia<sup>5</sup> and enable delivery of more intensive or dose-dense chemotherapy when indicated. However, concerns with respect to adverse events and costs led the American Society of Clinical Oncology (ASCO) to develop a clinical practice guideline for the use of CSFs in 1994 and updates on four occasions since then. This guideline represents the first major update since 2006 and addresses the strengths and

## THE BOTTOM LINE

**Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update****Guideline Question**

How should colony-stimulating factors (CSFs) be used in people with cancer?

**Target Population**

Adults or children with a solid tumor or lymphoma treated with chemotherapy

**Target Audience**

Medical oncologists, hematologists, oncology nurses, other clinicians who care for people with cancer, and patients

**Methods**

An Update Committee was convened to update clinical practice guideline recommendations based on a systematic review of the medical literature.

**Key Points**

- Primary prophylaxis with a CSF starting with the first cycle and continuing through subsequent cycles of chemotherapy is recommended in patients who have an approximately 20% or higher risk for febrile neutropenia based on patient-, disease- and treatment-related factors. Primary CSF prophylaxis should also be administered in patients receiving dose-dense chemotherapy when considered appropriate. Consideration should be given to alternative, equally effective, and safe chemotherapy regimens not requiring CSF support when available. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)
- Secondary prophylaxis with a CSF is recommended for patients who experienced a neutropenic complication from a prior cycle of chemotherapy (for which primary prophylaxis was not received), in which a reduced dose or treatment delay may compromise disease-free or overall survival or treatment outcome. In many clinical situations, dose reduction or delay may be a reasonable alternative. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)
- CSFs should not be routinely used for patients with neutropenia who are afebrile. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)
- CSFs should not be routinely used as adjunctive treatment with antibiotic therapy for patients with fever and neutropenia. However, CSFs should be considered in patients with fever and neutropenia who are at high risk for infection-associated complications or who have prognostic factors predictive of poor clinical outcomes. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)
- Dose-dense regimens with CSF support should only be used if supported by convincing efficacy data or within an appropriately designed clinical trial. Efficacy data support the use of dose-dense chemotherapy in the adjuvant treatment of high-risk breast cancer and the use of high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin in urothelial cancer. There are limited and conflicting data on the value of dose-dense regimens with CSF support in non-Hodgkin lymphoma, and it cannot routinely be recommended at this time. (Type: evidence based, benefits outweigh harms. Evidence quality: high for breast cancer and lymphoma; intermediate for urothelial cancer. Strength of recommendation: strong for breast cancer and lymphoma; moderate for urothelial cancer.)
- CSFs may be used alone, after chemotherapy, or in combination with plerixafor to mobilize peripheral-blood progenitor cells. Choice of mobilization strategy depends in part on type of cancer and type of transplantation. (Type: evidence based, benefits outweigh harms. Evidence quality: strong. Strength of recommendation: high.)

(continued on following page)

## THE BOTTOM LINE (CONTINUED)

- CSFs should be administered after autologous stem-cell transplantation to reduce the duration of severe neutropenia. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)
- CSFs may be administered after allogeneic stem-cell transplantation to reduce the duration of severe neutropenia. (Type: evidence based. Evidence quality: low. Strength of recommendation: weak.)
- Prophylactic CSFs for patients with diffuse aggressive lymphoma age  $\geq 65$  years treated with curative chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab) should be considered, particularly in the presence of comorbidities. (Type: evidence based, benefits outweigh harms. Evidence quality: intermediate. Strength of recommendation: moderate.)
- The use of CSFs in pediatric patients will almost always be guided by clinical protocols. As in adults, the use of CSFs is reasonable as primary prophylaxis for pediatric patients with a high likelihood of febrile neutropenia. Similarly, the use of CSFs for secondary prophylaxis or for therapy should be limited to high-risk patients. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)
- For pediatric indications in which dose-intense chemotherapy is known to have a survival benefit, such as Ewing sarcoma, CSFs should be used to enable the administration of these regimens. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)
- CSFs should not be used in pediatric patients with nonrelapsed acute lymphoblastic leukemia or nonrelapsed acute myeloid leukemia who do not have an infection. (Type: informal consensus. Evidence quality: intermediate. Strength of recommendation: moderate.)
- Pegfilgrastim, filgrastim, tbo-filgrastim, and filgrastim-sndz (and other biosimilars, as they become available) can be used for the prevention of treatment-related febrile neutropenia. The choice of agent depends on convenience, cost, and clinical situation. There have been no additional data comparing granulocyte CSFs and granulocyte-macrophage CSFs since the 2006 update; therefore, there is no change in the recommendation regarding their therapeutic equivalency. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)
- Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death resulting from injury to other organs, include the prompt administration of CSFs or pegylated granulocyte CSFs. (Type: formal consensus [by others], benefits outweigh harms. Evidence quality: intermediate. Strength of recommendation: moderate.)

**Qualifying Statements**

The Update Committee did not provide recommendations regarding the use of CSFs in adult patients with acute myeloid leukemia or myelodysplastic syndromes.

**Additional Resources**

More information, including a Data Supplement with additional evidence tables, a Methodology Supplement with information about evidence quality and strength of recommendations, slide sets, and clinical tools and resources, is available at [www.asco.org/guidelines/wbcgf](http://www.asco.org/guidelines/wbcgf). Patient information is available at [www.cancer.net](http://www.cancer.net).

ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate.

limitations of the use of CSFs across a range of settings in clinical oncology practice on the basis of an exhaustive review of the medical literature. The purpose of this guideline is to foster the appropriate use of these agents based on high-quality evidence from controlled clinical trials and a comprehensive understanding of the specific patient, disease, and treatment factors associated with the risk of neutropenic complications.

## GUIDELINE QUESTIONS

This clinical practice guideline considered the following clinical questions: (1) In adults treated with chemotherapy for a solid tumor or lymphoma, what factors should clinicians consider when selecting patients for primary prophylaxis of febrile neutropenia with a CSF? (2)

In adults treated with chemotherapy for a solid tumor or lymphoma, what factors should clinicians use to select patients for secondary prophylaxis of febrile neutropenia with a CSF? (3) Are there circumstances in which CSFs should be considered for the treatment of neutropenia in adults with cancer? (4) In what settings should CSFs be used to increase chemotherapy dose density? (5) What is the role of CSFs as adjuncts to progenitor-cell transplantation? (6) What is the role of CSFs in the setting of acute leukemia or myelodysplastic syndromes? (7) Should CSFs be avoided in patients receiving concomitant chemotherapy and radiation therapy? (8) Are there CSF recommendations that apply specifically to older adults and that differ from recommendations in younger adults? (9) How should CSFs be used in the pediatric population? (10) What are recommendations for the initiation, duration, dosing, and administration of CSFs? (11) Do CSFs differ in efficacy? (12) What is the role of CSFs in the treatment of radiation injury?

## METHODS

### Guideline Update Development Process

The Update Committee (members listed in Appendix Table A1, online only) met twice via Webinar and corresponded through e-mail. On the basis of the consideration of the evidence, the authors were asked to contribute to the development of the guideline, provide critical review, and finalize the guideline recommendations. Members of the Update Committee were responsible for reviewing and approving the final version of guideline, which was then circulated for external review and submitted to *Journal of Clinical Oncology* for editorial review and consideration for publication. All ASCO guidelines are ultimately reviewed and approved by the Update Committee and the ASCO Clinical Practice Guidelines Committee before publication.

The recommendations were developed by an Update Committee with multidisciplinary representation using a systematic review (October 1, 2005, through September 30, 2014) of phase III randomized controlled trials (RCTs), meta-analyses, systematic reviews, and clinical experience. When recommended by Update Committee members, results from selected phase II trials were considered. Articles were selected for inclusion in the systematic review of the evidence on the basis of the following criteria:

- Population: adults or children with cancer.
- Intervention: granulocyte CSFs (G-CSFs) and granulocyte macrophage CSFs (GM-CSFs) used to prevent or treat febrile neutropenia among patients treated with chemotherapy, to allow the delivery of dose-dense chemotherapy, to mobilize stem cells for transplantation, or to treat radiation injury.

Articles were excluded from the systematic review if they were meeting abstracts not subsequently published in peer-reviewed journals; editorials, commentaries, letters, news articles, case reports, or narrative reviews; or published in a language other than English. Excluded interventions were as follows: topical CSFs, CSFs as immunotherapy or vaccine adjuvant, perioperative CSFs, CSFs in allogeneic donors, CSFs for the prevention of mucositis, and granulocyte transfusion. Also excluded were studies in which the treatment arms received different anticancer drugs.

Outcomes of interest varied by clinical question and included neutropenia- and infection-related outcomes, progression-free and overall survival (OS), and outcomes related to stem-cell mobilization or transplantation.

The guideline recommendations were crafted, in part, using GLIDES (Guidelines Into Decision Support) methodology. Ratings for the type and strength of recommendation, evidence, and potential bias are provided with each recommendation. Detailed information about the methods used to develop this guideline update is available in the Methodology Supplement at [www.asco.org/guidelines/wbcgf](http://www.asco.org/guidelines/wbcgf), which includes an overview (eg, Update Committee composition, development process, and revision dates), literature

search and data extraction information, the recommendation development process, and a quality assessment.

The ASCO Committee and guidelines staff will work with co-chairs to monitor the medical literature and determine the need for future updates. This is the most recent information as of the publication date. For updates, the most recent information, and to submit new evidence, please visit [www.asco.org/guidelines/wbcgf](http://www.asco.org/guidelines/wbcgf) and the ASCO Guidelines Wiki ([www.asco.org/guidelineswiki](http://www.asco.org/guidelineswiki)).

### Guideline Disclaimer

This clinical practice guideline and other guidance published herein are provided by ASCO to assist providers in clinical decision making. The information herein should not be relied on as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Furthermore, the information is not intended to substitute for the independent professional judgment of the treating provider, because the information does not account for individual variation among patients. Recommendations are described as having high, moderate, or low confidence that a recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should not” indicates that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO provides this information on an as-is basis and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

### Guideline and Conflicts of Interest

The Expert Panel was assembled in accordance with the ASCO Conflict of Interest Management Procedures for Clinical Practice Guidelines (summarized at [www.asco.org/rwc](http://www.asco.org/rwc)). Members of the panel completed the ASCO disclosure form, which requires disclosure of financial and other interests relevant to the subject matter of the guideline, including relationships with commercial entities that are reasonably likely to experience direct regulatory or commercial impact as a result of promulgation of the guideline. Categories for disclosure include Employment; Leadership; Stock or Other Ownership; Honoraria, Consulting or Advisory Role; Speaker's Bureau; Research Funding; Patents, Royalties, Other Intellectual Property; Expert Testimony; Travel, Accommodations, Expenses; and Other Relationships. In accordance with these procedures, the majority of the members of the panel did not disclose any such relationships.

## RESULTS

### Characteristics of Studies Identified in the Literature Search

A total of 66 publications met eligibility criteria and form the evidentiary basis for the guideline recommendations. Evidence tables for each clinical question are provided in Data Supplement 1. Forty-one of the publications were RCTs, a majority of which were classified as having either a low or intermediate risk of bias. These classifications are provided in Data Supplement 2.



## RECOMMENDATIONS

## CLINICAL QUESTION 1

In adults treated with chemotherapy for a solid tumor or lymphoma, what factors should clinicians consider when selecting patients for primary prophylaxis of febrile neutropenia with a CSF?

**Recommendation 1**

Primary prophylaxis with a CSF starting in the first cycle and continuing through subsequent cycles of chemotherapy is recommended in patients who have an approximately 20% or higher risk for febrile neutropenia on the basis of patient-, disease-, and treatment-related factors. Primary CSF prophylaxis should also be administered in patients receiving dose-dense chemotherapy when considered appropriate. Consideration should be given to alternative, equally effective, and safe chemotherapy regimens not requiring CSF support when available. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)

**Literature Review Update and Analysis**

Of the 16 publications that addressed primary prophylaxis (eight meta-analyses, three clinical practice guidelines, three RCTs, and two systematic reviews), none prompted a change in the level of febrile neutropenia risk warranting primary prophylaxis with a CSF.<sup>6-21</sup> The 20% cutoff for febrile neutropenia risk has been maintained from the 2005 guideline based on the evidence from randomized trials, especially the trial of CSFs in patients with breast cancer,<sup>22</sup> in which the baseline risk for febrile neutropenia was 17%. Independent systematic reviews of eight trials with 2,156 patients with breast cancer confirmed that CSFs reduce the risk of febrile neutropenia, with possible reductions in the need for hospitalization and all-cause mortality, but with no effect on infection-related mortality.<sup>18</sup> Subsequent studies have shown that CSFs can reduce the risk of hospitalization for febrile neutropenia in elderly patients (age > 65 years) with solid tumors from 9% in all cycles to 5%,<sup>7</sup> but no other differences, such as in mortality, have been reported to justify treating a large number of patients who would not benefit and would experience potential toxicities and costs.

However, recent publications have provided additional information about the likely benefits of primary prophylaxis. Meta-analyses of RCTs conducted in varying patient populations have confirmed that primary prophylaxis with a CSF reduces the risk of febrile neutropenia during chemotherapy for a solid tumor or lymphoma.<sup>8,9,12,13,18,19</sup> Primary prophylaxis may also reduce the risk of hospitalization<sup>18</sup> and infection.<sup>8,19</sup> Results for all-cause or infection-related mortality are less consistent. A meta-analysis of 59 RCTs among patients with solid tumors or lymphoma reported that primary prophylaxis with a G-CSF was associated with a modest reduction in all-cause mortality compared with no primary prophylaxis (risk ratio [RR], 0.93; 95% CI, 0.90 to 0.96; absolute risk difference, -3.2%; 95% CI, -2.1% to -4.2%).<sup>14</sup> The greatest benefit was observed among patients who received dose-dense chemotherapy. In studies that evaluated the same dose and schedule of chemotherapy in different treatment arms, primary prophylaxis did not have a statistically significant effect on mortality.<sup>14</sup> Another large meta-analysis considered 148 RCTs of primary prophylaxis in children or adults who were receiving cancer chemotherapy or undergoing stem-cell transplantation (SCT).<sup>19</sup> Only RCTs

in which all study arms received the same chemotherapy or SCT conditioning regimen were included. On the basis of the 80 trials with all-cause mortality results, short-term all-cause mortality was 7.6% with primary prophylaxis and 8.0% without primary prophylaxis (RR, 0.95; 95% CI, 0.84 to 1.08). Results for infection-related mortality were also null (RR, 0.82; 95% CI, 0.66 to 1.02).<sup>19</sup> In contrast, the addition of a G-CSF was associated with a statistically significant reduction in infection-related mortality in a 2011 meta-analysis of 12 RCTs in adults with a solid tumor or lymphoma; risk was 1.5% among patients who received primary prophylaxis with a CSF, compared with 2.8% among patients who did not receive primary prophylaxis (RR, 0.55; 95% CI, 0.34 to 0.90).<sup>12</sup>

Adverse effects of CSFs include bone pain, but a randomized trial of naproxen versus placebo suggested that nonsteroidal anti-inflammatory drugs may reduce the incidence, duration, and severity of bone pain among CSF-treated patients.<sup>11</sup> Naproxen was administered at a dose of 500 mg twice per day starting on the day of pegfilgrastim administration and continuing for 5 to 8 days.

**Clinical Interpretation**

In addition to the risk of neutropenic complications associated with chemotherapy regimens in patients who are eligible for clinical trials, the risk and consequences of neutropenic complications may be increased in the elderly, those previously treated with chemotherapy or radiation therapy, and those with medical comorbidities (Table 1). Primary CSF prophylaxis has been consistently associated with significant reductions in the risk of febrile neutropenia and infectious complications and also enables delivery of full-dose chemotherapy on schedule when considered important in patient management.<sup>14</sup> Findings regarding infection-related and all-cause mortality have been less consistent. The ASCO Panel looks forward to reviewing validated and tested, user-friendly risk prediction tools when they are available, but at present, none can be fully recommended.

## CLINICAL QUESTION 2

Among adults treated with chemotherapy for a solid tumor or lymphoma, what factors should clinicians use to select patients for secondary prophylaxis of febrile neutropenia with a CSF?

**Table 1.** Patient Risk Factors for Febrile Neutropenia

Risk Factor
In addition to chemotherapy regimen and type of malignancy, consider the following factors when estimating patient's overall risk of febrile neutropenia <sup>23-25</sup> :
Age ≥ 65 years
Advanced disease
Previous chemotherapy or radiation therapy
Preexisting neutropenia or bone marrow involvement with tumor
Infection
Open wounds or recent surgery
Poor performance status or poor nutritional status
Poor renal function
Liver dysfunction, most notably elevated bilirubin
Cardiovascular disease
Multiple comorbid conditions
HIV infection

## Recommendation 2

Secondary prophylaxis with CSFs is recommended for patients who experienced a neutropenic complication from a previous cycle of chemotherapy (for which primary prophylaxis was not received), in which a reduced dose or treatment delay may compromise disease-free or OS or treatment outcome. In many clinical situations, dose reduction or delay may be a reasonable alternative. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)

## Literature Review Update and Analysis

The systematic review provided no new data. In particular, there were no new data supporting the use of CSFs to maintain dose-intensity in the treatment of metastatic disease, and the review found no demonstrable benefit in patients with metastatic lung, small-cell lung, colorectal, hormone-refractory prostate, or breast cancer.<sup>26</sup> To date, there have been no improvements in disease-free or OS reported for any common cancer with the use of CSFs to maintain dose-intensity, instead of dose reduction. The ASCO Panel recognizes that there may be individual patients who will not tolerate effective doses of chemotherapy without CSFs, as noted in the Guideline Disclaimer section.

## Clinical Interpretation

No changes have been made to the 2006 recommendations.

## CLINICAL QUESTION 3

Are there circumstances in which CSFs should be considered for the treatment of neutropenia in adults with cancer?

### Recommendation 3.1

*Therapy for patients with afebrile neutropenia.* CSFs should not be routinely used for patients with neutropenia who are afebrile. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)

### Recommendation 3.2

*Therapy for febrile patients with neutropenia.* CSFs should not be routinely used as adjunctive treatment with antibiotic therapy for patients with fever and neutropenia. However, CSFs should be considered in patients with fever and neutropenia who are at high risk for infection-associated complications or who have prognostic factors that are predictive of poor clinical outcomes. High-risk features include expected prolonged ( $> 10$  days) and profound ( $< 0.1 \times 10^9/L$ ) neutropenia, age  $> 65$  years, uncontrolled primary disease, pneumonia, hypotension and multiorgan dysfunction (sepsis syndrome), invasive fungal infection, or hospitalization at the time of fever development. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)

## Literature Review Update and Analysis

New data regarding therapeutic use of CSFs were provided by a single 2014 meta-analysis.<sup>27</sup> Treatment of febrile neutropenia with antibiotics plus a CSF did not reduce overall mortality compared with antibiotics alone (hazard ratio [HR], 0.74; 95% CI, 0.47 to 1.16).<sup>27</sup> However, the addition of a CSF did shorten the duration of neutropenia, fever, and antibiotic use and reduce the number of hospital stays  $> 10$  days.

**Table 2.** Patient Risk Factors for Poor Clinical Outcomes Resulting From Febrile Neutropenia or Infection<sup>28</sup>

Risk Factor
Sepsis syndrome
Age $> 65$ years
Profound neutropenia (absolute neutrophil count $< 0.1 \times 10^9/L$ )
Neutropenia expected to last $> 10$ days
Pneumonia
Invasive fungal infection
Other clinically documented infections
Hospitalization at time of fever
Prior episode of febrile neutropenia

## Clinical Interpretation

No changes have been made to the 2006 recommendations. Table 2 lists factors associated with poor clinical outcomes or complications resulting from febrile neutropenia or infection.<sup>28</sup>

## CLINICAL QUESTION 4

In what settings should CSFs be used to increase chemotherapy dose density?

### Recommendation 4

Dose-dense regimens with CSF support should only be used within an appropriately designed clinical trial or if supported by convincing efficacy data. Efficacy data support the use of CSFs with dose-dense chemotherapy in the adjuvant treatment of high-risk breast cancer and with high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-M-VAC) in urothelial cancer. There are limited and conflicting data on the value of dose-dense regimens with CSF support in non-Hodgkin lymphoma (NHL), and this cannot routinely be recommended at this time. (Type: evidence based, benefits outweigh harms. Evidence quality: high for breast cancer and lymphoma; intermediate for urothelial cancer. Strength of recommendation: strong for breast cancer and lymphoma; moderate for urothelial cancer.)

## Literature Review Update and Analysis

Twenty publications were identified (16 RCTs, two meta-analyses, one clinical practice guideline, and one single-arm phase II trial).<sup>14,16,29-46</sup> In nonmetastatic breast cancer, a 2010 meta-analysis reported that dose-dense chemotherapy (administered with CSFs) improves disease-free and OS, particularly among women with hormone receptor-negative disease.<sup>30</sup> A benefit was observed in three trials of so-called conserved dose-dense chemotherapy (similar doses of drugs in two treatment arms; HR, 0.84; 95% CI, 0.72 to 0.98) and in six trials of so-called modified dose-dense chemotherapy (different drugs or doses in two arms; HR, 0.85; 95% CI, 0.75 to 0.96). A survival benefit of dose-dense chemotherapy was also observed in a phase III clinical trial among women with  $\geq$  four positive lymph nodes.<sup>41</sup> Compared with conventionally scheduled epirubicin and cyclophosphamide followed by paclitaxel every 3 weeks, an intense dose-dense schedule of sequential epirubicin, paclitaxel, and cyclophosphamide every 2 weeks increased the toxicity of treatment but improved event-free and OS (OS: HR, 0.76; 95% CI, 0.59 to 0.97). More recently,

doxorubicin plus cyclophosphamide every 2 weeks followed by paclitaxel every 2 weeks was compared with continuous doxorubicin plus cyclophosphamide and/or weekly paclitaxel in the phase III SWOG (Southwest Oncology Group) S0221 trial. Disease-free survival was similar across treatment arms, but OS was highest with dosing every 2 weeks.<sup>31</sup> However, not all studies have reported a benefit of dose-dense chemotherapy in nonmetastatic breast cancer. Dose-dense sequential epirubicin and paclitaxel followed by intensified CMF treatment did not improve disease-free or OS compared with concomitant epirubicin and paclitaxel followed by intensified CMF treatment<sup>37</sup>; dose-intense neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide did not improve pathologic complete response rate compared with conventional neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide<sup>29</sup>; and neoadjuvant weekly doxorubicin and daily oral cyclophosphamide did not improve survival or pathologic complete response rate compared with standard neoadjuvant doxorubicin and cyclophosphamide.<sup>35</sup>

Among patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), two phase III clinical trials reported that a CSF-supported 14-day cycle of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (R-CHOP-14) was not more effective than the standard 21-day cycle (R-CHOP-21). In a UK study of patients age  $\geq 18$  years, 2-year OS was 82.7% in the R-CHOP-14 group and 80.8% in the R-CHOP-21 group (HR, 0.90; 95% CI, 0.70 to 1.15).<sup>33</sup> Similarly, in a multinational study of older patients (age 60 to 80 years) with DLBCL, 3-year OS was 69% in the R-CHOP-14 group and 72% in the R-CHOP-21 group (HR, 0.96; 95% CI, 0.73 to 1.26).<sup>34</sup> R-CHOP-14 also failed to improve progression-free or OS in a phase II/III trial of patients with untreated indolent B-cell NHL.<sup>46</sup>

A single phase III study assessed dose-intensified chemotherapy in lung cancer. Among patients with extensive-stage small-cell lung cancer, dose-intensified carboplatin plus etoposide every 21 days did not improve OS or progression-free survival compared with conventional carboplatin plus etoposide every 28 days.<sup>38</sup> Dose-dense or dose-intense therapy supported by G-CSFs also failed to improve OS or progression-free survival in studies of metastatic and locally advanced soft tissue sarcoma (standard *v* dose-intensified doxorubicin, ifosfamide, and dacarbazine),<sup>38</sup> high-grade osteosarcoma (3- *v* 2-week cycles of cisplatin and doxorubicin),<sup>40</sup> and advanced ovarian cancer (standard *v* intensified cyclophosphamide combined with epirubicin and cisplatin).<sup>42</sup>

Promising results with higher dose density or dose-intensity were reported in urothelial cancer. In a 7-year update of a phase III clinical trial, HD-M-VAC improved OS and progression-free survival among patients with advanced urothelial tract tumors. Median and 5-year OS were 15.1 months and 21.8% in the HD-M-VAC arm, compared with 14.9 months and 13.5% in the M-VAC arm (HR, 0.76; 95% CI, 0.58 to 0.99).<sup>43</sup> In a more recent single-arm phase II trial, neoadjuvant dose-dense M-VAC resulted in significant downstaging among patients with muscle-invasive urothelial cancer.<sup>32</sup>

### Clinical Interpretation

There are now several trials that support the use of CSFs in the setting of adjuvant dose-dense chemotherapy for high-risk breast cancer and one large study supporting CSF use with HD-M-VAC in urothelial cancer. Outside of a clinical trial, CSF-supported dose-dense chemotherapy should be restricted to these settings. Trials of

dose-dense chemotherapy in lymphoma, lung cancer, ovarian cancer, osteosarcoma, and sarcoma have been negative.

## CLINICAL QUESTION 5

What is the role of CSFs as adjuncts to progenitor-cell transplantation?

### Recommendation 5.1

CSFs may be used alone, after chemotherapy, or in combination with plerixafor to mobilize peripheral-blood progenitor cells. Choice of mobilization strategy depends in part on type of cancer and type of transplantation. (Type: evidence based, benefits outweigh harms. Evidence quality: strong. Strength of recommendation: high.)

### Literature Review Update and Analysis

Plerixafor, a CXCR4 receptor antagonist approved by the US Food and Drug Administration in 2008, is administered in combination with a G-CSF for the mobilization of stem cells for autologous transplantation in patients with NHL and multiple myeloma. The combination of a G-CSF and plerixafor has been evaluated in two phase III clinical trials.<sup>47,48</sup> Compared with a G-CSF alone, the combination of a G-CSF and plerixafor increased the number of patients who reached optimal CD34<sup>+</sup> cell targets within a specified number of apheresis days. The most common adverse events related to plerixafor were GI disorders and injection site reactions.

### Clinical Interpretation

The updated recommendation adds the option of a CSF in combination with plerixafor for the mobilization of peripheral-blood progenitor cells.

### Recommendation 5.2

CSFs should be administered after autologous SCT to reduce the duration of severe neutropenia. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)

### Recommendation 5.3

CSFs may be administered after allogeneic SCT to reduce the duration of severe neutropenia. (Type: evidence based. Evidence quality: low. Strength of recommendation: weak.)

### Literature Review Update and Analysis

Concerns about use of CSFs after allogeneic transplantation were raised by retrospective studies that reported an increased risk of acute graft-versus-host disease (GVHD) or treatment-related mortality among CSF recipients.<sup>49-51</sup> However, a 2006 meta-analysis of RCTs found that CSF use after allogeneic SCT reduced the risk of documented infections and did not have a statistically significant effect on grade 2 to 4 acute GVHD or treatment-related mortality.<sup>52</sup> In the combined group of autologous and allogeneic transplantation recipients, CSF use reduced duration of hospitalization, days of parenteral antibiotics, and risk of documented infection, although the association with documented infection was of borderline statistical significance ( $P = .05$ ). CSFs did not reduce the risk of infection-related mortality.

### Clinical Interpretation

The updated recommendation adds the option of administering CSFs after allogeneic transplantation. Studies published since the 2006 recommendation have not confirmed previous reports of increased risk of grade 2 to 4 GVHD or mortality in association with CSF use after allogeneic transplantation. Data are limited, however, and benefits of CSF use in this setting seem to be modest. A strong recommendation regarding CSF use after allogeneic transplantation was not possible at this time.

### CLINICAL QUESTION 6

What is the role of CSFs in the setting of acute leukemia or myelodysplastic syndromes?

#### Recommendation 6

The Update Committee did not provide recommendations regarding the use of CSFs in adults with acute myeloid leukemia or myelodysplastic syndromes.

### CLINICAL QUESTION 7

Should CSFs be avoided in patients receiving concomitant chemotherapy and radiation therapy?

#### Recommendation 7

CSFs should be avoided in patients receiving concomitant chemotherapy and radiation therapy, particularly involving the mediastinum. In the absence of chemotherapy, therapeutic use of CSFs may be considered in patients receiving radiation therapy alone if prolonged delays secondary to neutropenia are expected. (Type: evidence based. Evidence quality: high. Strength of recommendation: strong.)

#### Literature Review Update and Analysis

There were no new data.

### Clinical Interpretation

No changes have been made to the 2006 recommendations.

### CLINICAL QUESTION 8

Are there CSF recommendations that apply specifically to older adults and that differ from recommendations in younger adults?

#### Recommendation 8

Prophylactic CSFs for patients with diffuse aggressive lymphoma age  $\geq 65$  years treated with curative chemotherapy (CHOP-R) should be considered, particularly in the presence of comorbidities. (Type: evidence based, benefits outweigh harms. Evidence quality: intermediate. Strength of recommendation: moderate.)

#### Literature Review Update and Analysis

A single RCT evaluated the efficacy of primary prophylaxis among older patients. The trial enrolled patients age  $\geq 65$  years with performance status of 0 to 2 and either a solid tumor or NHL.<sup>7</sup> Patients received either pegfilgrastim starting with cycle one for all cycles or pegfilgrastim initiated after cycle one at the physician's discretion. Pegfilgrastim administered during all cycles reduced the risk of febrile neutropenia. Among patients with a solid tumor, the risk of febrile neutropenia across all cycles was 10% in the physician-discretion arm and 4% in the arm receiving pegfilgrastim in all cycles ( $P = .001$ ).

Given the low risk of febrile neutropenia in this group, most would not have qualified for CSFs outside of the clinical trial. For these patients at low risk of febrile neutropenia, CSFs should not be routinely prescribed. However, among patients with NHL, risk of febrile neutropenia across all cycles was 37% in the physician-discretion arm and 15% in the arm receiving pegfilgrastim in all cycles ( $P = .004$ ), justifying the use of a CSF as primary prophylaxis to prevent febrile neutropenia and hospitalization. However, the use of pegfilgrastim in all cycles did not result in fewer chemotherapy dose reductions or delays.

### Clinical Interpretation

The study by Balducci et al<sup>7</sup> provides support for the administration of pegfilgrastim in patients age  $\geq 65$  years who have a high enough risk of febrile neutropenia to justify CSF use, such as those with lymphoma. Whether patients would achieve as good or better results with prophylactic antibiotics is uncertain.<sup>53-55</sup>

### CLINICAL QUESTION 9

How should CSFs be used in the pediatric population?

#### Recommendation 9.1

The use of CSFs in pediatric patients will almost always be guided by clinical protocols. As in adults, a CSF is reasonable as the primary prophylaxis for pediatric patients with a high likelihood of febrile neutropenia. Similarly, a CSF as secondary prophylaxis or therapy should be limited to high-risk patients. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)

#### Literature Review Update and Analysis

A single meta-analysis evaluated the efficacy of prophylactic G-CSFs among children with a range of tumor types.<sup>56</sup> Prophylactic G-CSFs reduced the incidence of febrile neutropenia and the duration of severe neutropenia, hospitalization, and antibiotic use among children treated with myelosuppressive chemotherapy. However, prophylactic G-CSFs did not decrease documented infections.

### Clinical Interpretation

The 2006 study continues to be the benchmark for children receiving myelosuppressive chemotherapy. Although there were no differences in the rates of infection on the basis of CSF use, many pediatric regimens and pediatric clinical trials depend on rapid count recovery to allow for intensive treatment. For such regimens and such trials, CSFs should still be used if appropriate.

#### Recommendation 9.2

For pediatric indications in which dose-intensive chemotherapy is known to have a survival benefit, such as Ewing sarcoma, CSFs should be used to enable the administration of these regimens. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)

#### Literature Review Update and Analysis

Chemotherapy intensification through interval compression was evaluated in an RCT of patients age  $< 50$  years with newly diagnosed, localized Ewing sarcoma.<sup>57</sup> Chemotherapy consisted of alternating cycles of vincristine, doxorubicin, and cyclophosphamide and of ifosfamide plus etoposide administered every 21 or 14 days. All patients



received filgrastim. Primary tumor treatment was provided after four cycles in the standard arm and after six cycles in the intensified arm. Intensified treatment improved event-free survival; 5-year event-free survival was 73% in the intensified arm and 65% in the standard arm ( $P = .048$ ). OS was also higher in the intensified arm, although this result was of borderline statistical significance; 5-year OS was 83% in the intensified arm and 77% in the standard arm ( $P = .056$ ). Toxicity was similar in the two groups.

### Clinical Interpretation

In North America, as a result of these findings, the current standard of care for pediatric patients with Ewing sarcoma outside of a clinical trial is myelosuppressive chemotherapy every 2 weeks when tolerated. This is not feasible without CSF support.

### Recommendation 9.3

CSFs should not be used in pediatric patients with nonrelapsed acute lymphoblastic leukemia (ALL) or nonrelapsed acute myeloid leukemia (AML) who do not have an infection. (Type: informal consensus. Evidence quality: intermediate. Strength of recommendation: moderate.)

### Literature Review Update and Analysis

Evidence regarding the effects of prophylactic G-CSFs in pediatric ALL or AML is limited, but a 2007 randomized trial reported few benefits with prophylactic G-CSFs after induction therapy for de novo pediatric AML. G-CSFs shortened the duration of neutropenia but did not decrease the risk of febrile neutropenia, microbiologically documented infections, or infection-related mortality.<sup>58</sup> In the intent-to-treat analysis, 5-year event-free survival was 58% with G-CSFs and 59% without G-CSFs ( $P = .66$ ).

### Clinical Interpretation

The previous ASCO guideline noted that use of CSFs in children with ALL should be considered with caution. There is little new evi-

dence for or against the use of CSFs in ALL, although we can extrapolate from the AML experience. There is a theoretic concern that CSF use could stimulate the growth of leukemic blasts or leukemic stem cells, particularly in AML, and increase resistance to therapy and disease progression or relapse in both ALL and AML. The 2007 study<sup>58</sup> did not demonstrate an increased risk of relapse with CSF use among pediatric patients with AML, but exclusion criteria limit the generalizability of these results. Furthermore, CSF use did not decrease the risk for infectious complications. The routine use of CSF cannot be recommended for children with de novo AML and, by extension, for children with ALL.

### CLINICAL QUESTION 10

What are recommendations for the initiation, duration, dosing, and administration of CSFs?

### Recommendations

Recommendations for the administration of filgrastim, tbo-filgrastim, filgrastim-sndz, pegfilgrastim, and sargramostim are summarized in Table 3.

### Literature Review Update and Analysis

Recent randomized trials have addressed issues related to the duration and timing of G-CSF prophylaxis. The importance of continuing prophylaxis through all cycles of chemotherapy was assessed among women with breast cancer. Women who received pegfilgrastim prophylaxis during only the first two cycles of chemotherapy were more likely to develop febrile neutropenia than women who received pegfilgrastim prophylaxis during all six cycles of chemotherapy (36% v 10%, respectively).<sup>59</sup> The timing of pegfilgrastim (same day as chemotherapy v next day) was evaluated in randomized phase II trials of patients with breast cancer and lymphoma. Same-day pegfilgrastim resulted in a longer but statistically noninferior duration of severe neutropenia compared with next-day pegfilgrastim.<sup>60</sup> Administration of pegfilgrastim on day 2 versus day 4 was evaluated in a small trial

**Table 3.** Dosing and Administration of CSFs

Agent	Dosing and Administration
Filgrastim	Filgrastim should be started 1 to 3 days after administration of myelotoxic chemotherapy; in setting of high-dose therapy and autologous stem-cell rescue, filgrastim can be started 1 to 5 days after administration of high-dose therapy; filgrastim should be continued until reaching ANC $\geq 2$ to $3 \times 10^9/L$ ; for PBPC mobilization, filgrastim should be started $\geq 4$ days before first leukapheresis procedure and continued until last leukapheresis  In adults, recommended filgrastim dose is 5 $\mu g/kg$ per day for all clinical settings other than PBPC mobilization; in setting of PBPC mobilization, dose of 10 $\mu g/kg$ per day may be preferable; preferred route of filgrastim administration is subcutaneous
Filgrastim-sndz	Same as for filgrastim
Tbo-filgrastim	Tbo-filgrastim should be started 1 to 3 days after administration of myelotoxic chemotherapy; in adults, recommended tbo-filgrastim dose is 5 $\mu g/kg$ per day; preferred route of tbo-filgrastim administration is subcutaneous
Pegfilgrastim	Pegfilgrastim 6 mg should be administered once 1 to 3 days after chemotherapy if possible; because some patients will not be able to return for dose of pegfilgrastim because of distance or immobility, for instance, alternatives to consider may include self-administered filgrastim or tbo-filgrastim or same-day pegfilgrastim, recognizing that although same-day pegfilgrastim is not as effective as later pegfilgrastim, it is better than no pegfilgrastim; pegfilgrastim is also available in a timed automated-inject device that delivers 6 mg of pegfilgrastim subcutaneously, 27 hours after it is placed on skin and activated; pegfilgrastim is not currently indicated for stem-cell mobilization; 6-mg formulation should not be used in infants, children, or small adolescents who weigh $< 45$ kg
Sargramostim	Because GM-CSFs have been licensed specifically for use in mobilization and after transplantation of autologous PBPCs, after autologous or allogeneic bone marrow transplantation, and for AML, manufacturer's instructions for administration are limited to those clinical settings; GM-CSFs should be initiated on day of bone marrow infusion and not $< 24$ hours after last chemotherapy and 12 hours after most recent radiotherapy; GM-CSFs should be continued until ANC $> 1.5 \times 10^9/L$ for 3 consecutive days is achieved; drug should be discontinued early or dose reduced by 50% if ANC increases to $> 20 \times 10^9/L$ ; recommended dose for adults is 250 $\mu g/m^2$ per day

Abbreviations: AML, acute myeloid leukemia; ANC, absolute neutrophil count; CSF, colony-stimulating factor; GM-CSF, granulocyte macrophage colony-stimulating factor; PBPC, peripheral-blood progenitor cell.

of older patients with aggressive NHL<sup>61</sup> and a larger trial of women with node-positive breast cancer.<sup>62</sup> Although the NHL trial suggested that day-4 pegfilgrastim may reduce the incidence of severe leukocytopenias, the breast cancer trial reported that day-2 and day-4 pegfilgrastim produced similar rates of febrile neutropenia, infection, and grade 4 leukopenia.

### **Clinical Interpretation**

The recommendation for pegfilgrastim administration includes off-label use (administration of pegfilgrastim on same day as chemotherapy in certain circumstances). Evidence suggests that pegfilgrastim administered 1 to 3 days after chemotherapy results in a lower risk of infection than pegfilgrastim administered on the same day as chemotherapy,<sup>60</sup> but clinicians should not be prohibited from using same-day pegfilgrastim if it provides the only feasible means of CSF administration for certain patients.

## **CLINICAL QUESTION 11**

Do CSFs differ in efficacy?

### **Recommendation 11**

Pegfilgrastim, filgrastim, tbo-filgrastim, and filgrastim-sndz (and other biosimilars as they become available) can be used for the prevention of treatment-related febrile neutropenia. The choice of agent depends on convenience, cost, and clinical situation. There have been no additional data comparing G-CSF and GM-CSF since the 2006 update; therefore, there has been no change in the recommendation regarding their therapeutic equivalency. (Type: evidence based, benefits outweigh harms. Evidence quality: high. Strength of recommendation: strong.)

### **Literature Review Update and Analysis**

In a 2011 meta-analysis of primary G-CSFs in adults undergoing chemotherapy for a solid tumor or lymphoma, filgrastim, pegfilgrastim, and lenograstim (which is not currently available in United States) each significantly reduced the risk of febrile neutropenia.<sup>9</sup> A comparison of pegfilgrastim and filgrastim was based on five clinical trials and suggested that pegfilgrastim was more effective than filgrastim at reducing the risk of febrile neutropenia (RR, 0.66; 95% CI, 0.44 to 0.98).<sup>9</sup> A number of small RCTs comparing pegfilgrastim and filgrastim have also been conducted in other patient populations, including pediatric patients<sup>63,64</sup> and adults who have undergone autologous SCT.<sup>65-67</sup> A statistically significant benefit of pegfilgrastim over filgrastim in the incidence of febrile neutropenia was reported after a study of patients with multiple myeloma who had undergone autologous peripheral-blood SCT, but the sample size and the differing timing of G-CSF administration limit the conclusions that can be drawn from this study; pegfilgrastim was started on day 1 after stem-cell infusion, and filgrastim was started on day 5 after stem-cell infusion.<sup>67</sup>

Tbo-filgrastim, a nonglycosylated recombinant methionyl human granulocyte colony-stimulating growth factor, was approved by the US Food and Drug Administration in 2012 for reduction in the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. RCTs conducted in patients with breast cancer, lung cancer, and NHL have suggested that the safety and efficacy of tbo-filgrastim are similar to those of

filgrastim.<sup>68-71</sup> In a meta-analysis of the three trials, the adjusted difference in the rate of first-cycle febrile neutropenia between tbo-filgrastim and filgrastim was 1.7% (95% CI, -3.8% to 7.1%), again demonstrating no statistically significant difference between the two drugs for this outcome.<sup>71</sup>

Filgrastim-sndz, approved in March 2015, was the first biosimilar product approved in the United States. Approval was based on structural and functional characterization, animal data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data, and other clinical safety and effectiveness data. Filgrastim and filgrastim-sndz were compared in a phase III noninferiority trial. Full results from the trial had not been published at the time the ASCO guideline was submitted for publication. However, an abstract was published as part of the 56th Annual Meeting of the American Society of Hematology (online publication only).<sup>72</sup> The study enrolled women who were eligible for neoadjuvant or adjuvant docetaxel, doxorubicin, and cyclophosphamide chemotherapy for breast cancer. Study participants were randomly assigned to one of four groups: filgrastim-sndz in all cycles; filgrastim-sndz in cycle one, then alternating filgrastim and filgrastim-sndz in subsequent cycles; filgrastim in cycle one, then alternating filgrastim-sndz and filgrastim in subsequent cycles; or filgrastim in all cycles. Filgrastim-sndz was noninferior to filgrastim with respect to duration of severe neutropenia after cycle one chemotherapy. Switching between the two drugs did not seem to affect efficacy or safety.

### **Clinical Interpretation**

Filgrastim, tbo-filgrastim, filgrastim-sndz, and pegfilgrastim are all effective in the reduction of the risk of febrile neutropenia. Choice of agent will depend on factors such as convenience and cost and may in some cases be dictated by the patient's treatment plan (eg, weekly chemotherapy).

## **CLINICAL QUESTION 12**

What is the role of CSFs in the treatment of radiation injury?

### **Recommendation 12**

Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs or pegylated G-CSFs.<sup>73-75</sup> (Type: formal consensus [by others], benefits outweigh harms. Evidence quality: intermediate. Strength of recommendation: moderate.)

### **Literature Review Update and Analysis**

This question has not been addressed by placebo-controlled trials in humans and, because of ethical considerations, is unlikely to be addressed. An expert panel convened by the WHO in 2009 considered data from animal experiments, case series and case reports, and studies of patients treated with chemotherapy and made a strong consensus recommendation for the administration of GM-CSFs or G-CSFs in the management of hematopoietic syndrome resulting from exposure to ionizing radiation.<sup>73</sup> The panel noted that health care providers "should consider initiating cytokine therapy for exposures of  $\geq 2$  Gy and/or a significant decrease in the absolute lymphocyte count, or when it is anticipated that neutropenia of less than  $0.5 \times 10^9$  cells per liter will persist for  $\geq 7$  days."<sup>73p6</sup> The recommended timing of cytokine initiation was within 24 hours of exposure.

## Clinical Interpretation

Accidental or intentional (eg, resulting from terrorist attack or war) total-body radiation leads to probable or certain death resulting from bone marrow failure at doses of 3 to 10 Gy without supportive care, CSFs, and/or bone marrow transplantation.<sup>76-78</sup> Doses below that level are almost always survivable with excellent nursing care; higher doses are lethal because of injury to other organs, such as the GI tract. The chance of mortality from any radiation dose rises with combined injuries to the skin, lungs, and so on.<sup>79</sup>

Hematopoietic growth factors can increase the survival, proliferation, amplification, and differentiation of granulocyte progenitors to produce neutrophils. Although no prospective randomized trials have been carried out to determine the benefit of hematopoietic growth factors in humans exposed to accidental or intentional radiation injury, they have been used in radiation accident victims, and neutrophil recovery seems to have been hastened in 25 of 28 patients (from Radiation Emergency Assistance Center/Training Site registry). In animal models, prompt administration of hematopoietic growth factors after otherwise lethal total-body radiation exposure has dramatically increased survival.<sup>80-85</sup>

## PATIENT AND CLINICIAN COMMUNICATION

For adults with a solid tumor or lymphoma who receive chemotherapy regimens that carry a high risk of febrile neutropenia ( $\geq 20\%$ ), primary prophylaxis substantially reduces the risk of a serious treatment complication and is recommended for most patients. However, for many commonly used chemotherapy regimens, the risk of febrile neutropenia is  $< 20\%$ , and more individualized decisions about CSF use are required. The risk of neutropenic complications and the importance of primary prophylaxis will vary with factors such as age, comorbidity, and other treatment-related considerations. It is important that in addition to understanding the evidence-based benefits and other risks of treatment, patients learn about the risk of febrile neutropenia as part of routine chemotherapy education.

The most common adverse effect of G-CSFs is bone pain, and patients should be encouraged to report this and other adverse effects to their treatment team. Acetaminophen and nonsteroidal anti-inflammatory drugs are common first-line options for the prevention or treatment of G-CSF-related bone pain in adults. Other approaches that may be considered include antihistamines, opioids, and G-CSF dose reduction.<sup>86</sup>

## HEALTH DISPARITIES

Although ASCO clinical practice guidelines represent expert recommendations on the best practices in disease management to provide the highest level of cancer care, it is important to note that many patients have limited access to medical care. Racial and ethnic disparities in health care contribute significantly to this problem in the United States. Patients with cancer who are members of racial/ethnic minorities disproportionately experience comorbidities, experience more substantial obstacles to receiving care, are more likely to be uninsured, and are at greater risk of receiving care of poor quality than other Americans.<sup>87</sup> Many other patients lack access to care because of their geographic location or distance from appropriate treatment facilities. Analyses of SEER-Medicare data suggest that first-cycle CSF

use among women with breast cancer is less common in nonwhites<sup>88</sup> and women of low socioeconomic status<sup>89</sup> and varies substantially by geographic region.<sup>88</sup> Awareness of these disparities in access to care should be considered in the context of this clinical practice guideline, and health care providers should strive to deliver the highest level of cancer care to these vulnerable populations.

## MULTIPLE CHRONIC CONDITIONS

Creating evidence-based recommendations regarding the treatment of patients with multiple chronic conditions can be challenging. Patients with multiple chronic conditions are a complex and heterogeneous population and are frequently excluded from clinical trials.

In the case of febrile neutropenia, observational studies have provided important information about the impact of comorbidity. A 2014 systematic review reported that the presence of comorbid conditions increased the risk of febrile neutropenia among patients with cancer treated with chemotherapy.<sup>23</sup> Both the number and types of comorbidities may be important to consider. Among patients with breast, lung, prostate, or colorectal cancer in the SEER-Medicare database, the risk of febrile neutropenia increased with the number of comorbid conditions.<sup>24</sup> Compared with patients with no comorbid conditions, patients with  $\geq$  three comorbid conditions had an 81% increased risk of febrile neutropenia. The presence of renal, hepatic, or cardiovascular disease has been associated with febrile neutropenia or febrile neutropenia-related hospitalization in patients with NHL treated with CHOP-based chemotherapy.<sup>90,91</sup> The optimal approach to incorporating comorbidity information in risk prediction tools continues to be explored, but comorbidity remains an important predictor of febrile neutropenia, even after accounting for factors such as cancer type and age.<sup>25</sup>

## COST IMPLICATIONS

Although the 2006 Update Committee extensively discussed the cost of CSFs, it recommended CSF use when the febrile neutropenia rate was approximately  $\geq 20\%$  based on clinical impact alone, because of the consensus that reduction in febrile neutropenia itself was an important clinical outcome. Since the 2006 update, original data from randomized trials have been limited.

Cost-effectiveness analyses of primary versus secondary prophylaxis with G-CSFs have produced varying results. In a model that considered three different strategies (no primary prophylaxis, 10 days of filgrastim, or one dose of pegfilgrastim) among patients receiving R-CHOP-21 for DLBCL, primary prophylaxis was not cost effective from the perspective of a publicly funded health care system. Costs associated with no primary prophylaxis, filgrastim prophylaxis, and pegfilgrastim prophylaxis were Canadian \$7,314, \$13,947, and \$16,290, respectively.<sup>92</sup> The incremental cost effectiveness for primary prophylaxis with filgrastim versus no primary prophylaxis was Canadian \$5,796,000 per quality-adjusted life-year, far outside accepted bounds. In a United Kingdom-based model of cost among patients with breast cancer, the most cost-effective strategy (primary prophylaxis, secondary prophylaxis, or no G-CSFs) depended on patient characteristics and risk of febrile neutropenia. Of the three types of G-CSFs evaluated, pegfilgrastim seemed to be more cost effective than

filgrastim or lenograstim.<sup>93</sup> A cost benefit may be more apparent in the United States, as a result of higher health care costs,<sup>94</sup> but cost effectiveness will vary by factors such as the risk of febrile neutropenia.

Randomized trials have assessed the efficacy of reduced dosages or less frequent administration of prophylactic G-CSFs. A study in the United Kingdom randomly assigned 172 patients with breast cancer to primary prophylaxis with a G-CSF during all six cycles of chemotherapy or during just the first two cycles. Prophylactic G-CSF during only the first two cycles of chemotherapy was cost saving but resulted in a higher rate of febrile neutropenia than a G-CSF during all cycles (36% v 10%, respectively).<sup>95</sup> A reduced dose of lenograstim (50 µg/body) was evaluated in a small cross-over study of patients with NHL in Japan and compared favorably with a 75-µg/body dose of filgrastim.<sup>96</sup> In the absence of more definitive data, the consensus of the 2015 Update Committee is that clinicians should adhere to current product labeling.

There do seem to be opportunities to improve G-CSF use in the community. The overuse of CSFs was one of the 2012 ASCO Choosing Wisely recommendations: “Don’t use white cell stimulating factors for primary prevention of febrile neutropenia for patients with less than 20% risk for this complication.”<sup>97p3</sup> To reduce CSF use in patients receiving low-risk chemotherapy regimens, Fishman et al<sup>98</sup> instituted real-time peer-to-peer consultation regarding pegfilgrastim use. Among patients receiving low-risk chemotherapy regimens, pegfilgrastim use decreased from 52 units in the fourth quarter of 2009 to 15 units in the third quarter of 2010 (71% decrease) with no adverse consequences.

Although questions remain about the cost effectiveness of G-CSFs in certain settings, the 2015 Update Committee has reiterated the position that G-CSF prophylaxis should be driven by clinical considerations and not by cost. CSF use is recommended when the febrile neutropenia rate is  $\geq 20\%$  based on clinical impact alone, because of the consensus that reduction in febrile neutropenia itself is an important clinical outcome. The 2015 Update Committee has recognized, again, that these are expensive agents with the potential for overuse. As stated, when alternative regimens are available that offer

equivalent efficacy without the need for CSF support, these alternative regimens should be used.

## GUIDELINE IMPLEMENTATION

ASCO guidelines are developed for implementation across health settings. Barriers to implementation include the need to increase awareness of the guideline recommendations among front-line practitioners and survivors of cancer and caregivers and also to provide adequate services in the face of limited resources. The guideline Bottom Line Box was designed to facilitate implementation of recommendations. This guideline will be distributed widely through the ASCO Practice Guideline Implementation Network. ASCO guidelines are posted on the ASCO Web site and most often published in *Journal of Clinical Oncology* and *Journal of Oncology Practice*.

## ADDITIONAL RESOURCES

More information, including a Data Supplement with additional evidence tables, a Methodology Supplement with information about evidence quality and strength of recommendations, slide sets, and clinical tools and resources, is available at [www.asco.org/guidelines/wbcgf](http://www.asco.org/guidelines/wbcgf). Patient information is available at [www.cancer.net](http://www.cancer.net). Visit [www.asco.org/guidelineswiki](http://www.asco.org/guidelineswiki) to provide comments on the guideline or to submit new evidence.

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at [www.jco.org](http://www.jco.org).

## AUTHOR CONTRIBUTIONS

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

## REFERENCES

- Bennett CL, Djulbegovic B, Norris LB, et al: Colony-stimulating factors for febrile neutropenia during cancer therapy. *N Engl J Med* 368:1131-1139, 2013
- Culakova E, Thota R, Poniewierski MS, et al: Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: A nationwide prospective cohort study. *Cancer Med* 3:434-444, 2014
- Weycker D, Li X, Edelsberg J, et al: Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. *J Oncol Pract* 10:47-54, 2015
- Bodey GP, Buckley M, Sathe YS, et al: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. *Ann Intern Med* 64:328-340, 1966
- Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. *N Engl J Med* 325:164-170, 1991
- Apapro MS, Bohlius J, Cameron DA, et al: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. *Eur J Cancer* 47:8-32, 2011
- Balducci L, Al-Halawani H, Charu V, et al: Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. *Oncologist* 12:1416-1424, 2007
- Bohlius J, Herbst C, Reiser M, et al: Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. *Cochrane Database Syst Rev* 8:CD003189, 2008
- Cooper KL, Madan J, Whyte S, et al: Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: Systematic review and meta-analysis. *BMC Cancer* 11:404, 2011
- Herbst C, Naumann F, Kruse EB, et al: Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. *Cochrane Database Syst Rev* 1:CD007107, 2009
- Kirshner JJ, Heckler CE, Janelins MC, et al: Prevention of pegfilgrastim-induced bone pain: A phase III double-blind placebo-controlled randomized clinical trial of the University of Rochester Cancer Center Clinical Community Oncology Program research base. *J Clin Oncol* 30:1974-1979, 2012
- Kuderer NM: Meta-analysis of randomized controlled trials of granulocyte colony-stimulating factor prophylaxis in adult cancer patients receiving chemotherapy. *Cancer Treat Res* 157:127-143, 2011
- Kuderer NM, Dale DC, Crawford J, et al: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. *J Clin Oncol* 25:3158-3167, 2007
- Lyman GH, Dale DC, Culakova E, et al: The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: A systematic review and meta-analysis of randomized controlled trials. *Ann Oncol* 24:2475-2484, 2013
- Lyman GH, Dale DC, Wolff DA, et al: Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: A systematic review. *J Clin Oncol* 28:2914-2924, 2010
- National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors (version 2.2014).



17. Papaldo P, Ferretti G, Di Cosimo S, et al: Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? *J Clin Oncol* 24:3048-3055, 2006
18. Renner P, Milazzo S, Liu JP, et al: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. *Cochrane Database Syst Rev* 10:CD007913, 2012
19. Sung L, Nathan PC, Alibhai SM, et al: Meta-analysis: Effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. *Ann Intern Med* 147:400-411, 2007
20. Vehreschild JJ, Böhme A, Cornely OA, et al: Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). *Ann Oncol* 25:1709-1718, 2014
21. Wildiers H, Reiser M: Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. *Crit Rev Oncol Hematol* 77:221-240, 2011
22. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. *J Clin Oncol* 23:1178-1184, 2005
23. Lyman GH, Abella E, Pettengell R: Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. *Crit Rev Oncol Hematol* 90:190-199, 2014
24. Hosmer W, Malin J, Wong M: Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. *Support Care Cancer* 19:333-341, 2011
25. Lyman GH, Kuderer NM, Crawford J, et al: Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. *Cancer* 117:1917-1927, 2011
26. Smith TJ, Hillner BE: A way forward on the medically appropriate use of white cell growth factors. *J Clin Oncol* 30:1584-1587, 2012
27. Mhaskar R, Clark OA, Lyman G, et al: Colony-stimulating factors for chemotherapy-induced febrile neutropenia. *Cochrane Database Syst Rev* 10:CD003039, 2014
28. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. *J Clin Oncol* 24:3187-3205, 2006
29. Arun BK, Dhingra K, Valero V, et al: Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: Long-term results. *Oncologist* 16:1527-1534, 2011
30. Bonilla L, Ben-Aharon I, Vidal L, et al: Dose-dense chemotherapy in nonmetastatic breast cancer: A systematic review and meta-analysis of randomized controlled trials. *J Natl Cancer Inst* 102:1845-1854, 2010
31. Budd GT, Barlow WE, Moore HC, et al: SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. *J Clin Oncol* 33:58-64, 2015
32. Choueiri TK, Jacobus S, Bellmunt J, et al: Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: Pathologic, radiologic, and biomarker correlates. *J Clin Oncol* 32:1889-1894, 2014
33. Cunningham D, Hawkes EA, Jack A, et al: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles. *Lancet* 381:1817-1826, 2013
34. Delarue R, Tilly H, Mounier N, et al: Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): A randomised phase 3 trial. *Lancet Oncol* 14:525-533, 2013
35. Ellis GK, Barlow WE, Gralow JR, et al: Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. *J Clin Oncol* 29:1014-1021, 2011
36. Fayette J, Penel N, Chevreau C, et al: Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. *Invest New Drugs* 27:482-489, 2009
37. Gogas H, Dafni U, Karina M, et al: Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III trial. *Breast Cancer Res Treat* 132:609-619, 2012
38. Heigener DF, Manegold C, Jäger E, et al: Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage. *Am J Clin Oncol* 32:61-64, 2009
39. Hertzberg M, Matthews JP, Stone JM, et al: A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data—Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial. *Am J Hematol* 89:536-541, 2014
40. Lewis IJ, Nooij MA, Whelan J, et al: Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. *J Natl Cancer Inst* 99:112-128, 2007
41. Moebus V, Jackisch C, Lueck HJ, et al: Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: Mature results of an AGO phase III study. *J Clin Oncol* 28:2874-2880, 2010
42. Ray-Coquard I, Paraiso D, Guastalla JP, et al: Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer: a randomised study from the GINECO group. *Br J Cancer* 97:1200-1205, 2007
43. Sternberg CN, de Mulder P, Schornagel JH, et al: Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. *Eur J Cancer* 42:50-54, 2006
44. Verdonck LF, Notenboom A, de Jong DD, et al: Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: A phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). *Blood* 109:2759-2766, 2007
45. Vriens BE, Aarts MJ, de Vries B, et al: Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer. *Eur J Cancer* 49:3102-3110, 2013
46. Watanabe T, Tobinai K, Shibata T, et al: Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. *J Clin Oncol* 29:3990-3998, 2011
47. DiPersio JF, Micallef IN, Stiff PJ, et al: Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. *J Clin Oncol* 27:4767-4773, 2009
48. DiPersio JF, Stadtmauer EA, Nademanee A, et al: Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. *Blood* 113:5720-5726, 2009
49. Remberger M, Naseh N, Aschan J, et al: G-CSF given after hematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. *Bone Marrow Transplant* 32:217-223, 2003
50. Ringden O, Hassan Z, Karlsson R, et al: Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. *Transplantation* 90:1022-1029, 2010
51. Ringden O, Labopin M, Gorin NC, et al: Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: A study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol* 22:416-423, 2004
52. Dekker A, Bulley S, Beyene J, et al: Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. *J Clin Oncol* 24:5207-5215, 2006
53. Bucaneve G, Micozzi A, Menichetti F, et al: Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. *N Engl J Med* 353:977-987, 2005
54. Cullen M, Steven N, Billingham L, et al: Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. *N Engl J Med* 353:988-998, 2005
55. Gafter-Gvili A, Fraser A, Paul M, et al: Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. *Ann Intern Med* 142:979-995, 2005
56. Wittman B, Horan J, Lyman GH: Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: A meta-analysis of randomized controlled trials. *Cancer Treat Rev* 32:289-303, 2006
57. Womer RB, West DC, Krailo MD, et al: Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children's Oncology Group. *J Clin Oncol* 30:4148-4154, 2012
58. Lehrnbecher T, Zimmermann M, Reinhardt D, et al: Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. *Blood* 109:936-943, 2007
59. Aarts MJ, Peters FP, Mandigers CM, et al: Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast

cancer at risk for febrile neutropenia. *J Clin Oncol* 31:4290-4296, 2013

60. Burris HA, Belani CP, Kaufman PA, et al: Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin's lymphoma: Results of four multicenter, double-blind, randomized phase II studies. *J Oncol Pract* 6:133-140, 2010
61. Zwick C, Hartmann F, Zeynalova S, et al: Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. *Ann Oncol* 22:1872-1877, 2011
62. Loibl S, Mueller V, von Minckwitz G, et al: Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study. (GBG 33). *Support Care Cancer* 19:1789-1795, 2011
63. Cesaro S, Nesi F, Tridello G, et al: A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant. *PLoS One* 8:e53252, 2013
64. Fox E, Widemann BC, Hawkins DS, et al: Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. *Clin Cancer Res* 15:7361-7367, 2009
65. Castagna L, Bramanti S, Levis A, et al: Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. *Ann Oncol* 21:1482-1485, 2010
66. Gerds A, Fox-Geiman M, Dawravoo K, et al: Randomized phase III trial of pegfilgrastim versus filgrastim after autologous peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant* 16:678-685, 2010
67. Martino M, Praticò G, Messina G, et al: Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. *Eur J Haematol* 77:410-415, 2006
68. del Giglio A, Eniu A, Ganea-Motan D, et al: XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. *BMC Cancer* 8:332, 2008
69. Engert A, Griskevicius L, Zyuzgin Y, et al: XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. *Leuk Lymphoma* 50:374-379, 2009
70. Gatzemeier U, Ciuleanu T, Dediu M, et al: XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. *J Thorac Oncol* 4:736-740, 2009
71. Engert A, del Giglio A, Bias P, et al: Incidence of febrile neutropenia and myelotoxicity of chemotherapy: A meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. *Onkologie* 32:599-604, 2009
72. Blackwell K, Semiglazov V, Gascon P, et al: A comparison of proposed biosimilar and originator filgrastim for the prevention of neutropenia in patients with breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: Phase III, randomized, double-blind trial (the PIONEER study). *Blood* 124, 2014
73. Dainiak N, Gent RN, Carr Z, et al: First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation. *Disaster Med Public Health Prep* 5:202-212, 2011
74. Dainiak N, Waselenko JK, Armitage JO, et al: The hematologist and radiation casualties. *Hematology Am Soc Hematol Educ Program*. 2003:473-488, 2003
75. Waselenko JK, MacVittie TJ, Blakely WF, et al: Medical management of the acute radiation syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group. *Ann Intern Med* 140:1037-1051, 2004
76. Hall EJ: *Acute Effects of Total-Body Irradiation, Radiobiology for the Radiologist*. Philadelphia, PA, Lippincott Williams & Wilkins, 2000, pp 124-135
77. Schull WJ: The somatic effects of exposure to atomic radiation: The Japanese experience, 1947-1997. *Proc Natl Acad Sci U S A* 95:5437-5441, 1998
78. US Department of Health and Human Services: Agency for Toxic Substances and Disease Registry: Toxicological Profile for Cesium. <http://www.atsdr.cdc.gov/toxprofiles/tp157.pdf>
79. Barabanova AV: Acute radiation syndrome with cutaneous syndrome, in Ricks RC BM, O'Hara FM (eds): *The Medical Basis for Radiation-Accident Preparedness: The Clinical Care of Victims*. Boca Raton, FL, CRC Press, 2002, pp 217-224
80. Farese AM, Casey DB, Vigneulle RM, et al: A single dose of pegylated leridistim significantly improves neutrophil recovery in sublethally irradiated rhesus macaques. *Stem Cells* 19:514-521, 2001
81. Farese AM, Hunt P, Grab LB, et al: Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. *J Clin Invest* 97:2145-2151, 1996
82. Farese AM, Williams DE, Seiler FR, et al: Combination protocols of cytokine therapy with interleukin-3 and granulocyte-macrophage colony-stimulating factor in a primate model of radiation-induced marrow aplasia. *Blood* 82:3012-3018, 1993
83. MacVittie TJ, Farese AM, Herodin F, et al: Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor. *Blood* 87:4129-4135, 1996
84. Nash RA, Schuening FG, Seidel K, et al: Effect of recombinant canine granulocyte-macrophage colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. *Blood* 83:1963-1970, 1994
85. Neelis KJ, Dubbelman YD, Qingliang L, et al: Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. *Exp Hematol* 25:1084-1093, 1997
86. Lambertini M, Del Mastro L, Bellodi A, et al: The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). *Crit Rev Oncol Hematol* 89:112-128, 2014
87. Mead H, Cartwright-Smith L, Jones K, et al: *Racial and Ethnic Disparities in U.S. Health Care: A Chartbook*. New York, NY, Commonwealth Fund, 2008
88. Rajan SS, Lyman GH, Carpenter WR, et al: Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer. *Breast Cancer Res Treat* 127:511-520, 2011
89. Hershman DL, Wilde ET, Wright JD, et al: Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. *J Clin Oncol* 30:806-812, 2012
90. Lyman GH, Delgado DJ: Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. *Cancer* 98:2402-2409, 2003
91. Lyman GH, Morrison VA, Dale DC, et al: Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. *Leuk Lymphoma* 44:2069-2076, 2003
92. Lathia N, Isogai PK, De Angelis C, et al: Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients. *J Natl Cancer Inst* 105:1078-1085, 2013
93. Whyte S, Cooper KL, Stevenson MD, et al: Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom. *Value Health* 14:465-474, 2011
94. Hirsch BR, Lyman GH: Pharmacoeconomics of the myeloid growth factors: A critical and systematic review. *Pharmacoeconomics* 30:497-511, 2012
95. Aarts MJ, Grutters JP, Peters FP, et al: Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. *J Clin Oncol* 31:4283-4289, 2013
96. Hashino S, Morioka M, Irie T, et al: Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma. *Int J Lab Hematol* 30:292-299, 2008
97. Schnipper LE, Smith TJ, Raghavan D, et al: American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. *J Clin Oncol* 30:1715-1724, 2012
98. Fishman ML, Kumar A, Davis S, et al: Guideline-based peer-to-peer consultation optimizes pegfilgrastim use with no adverse clinical consequences. *J Oncol Pract* 8:e14s-e17s, 2012 (suppl)

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

### Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [jco.ascopubs.org/site/ifc](http://jco.ascopubs.org/site/ifc).

#### Thomas J. Smith

**Stock or Other Ownership:** United Healthcare

#### Kari Bohlke

No relationship to disclose

#### Gary Lyman

**Consulting or Advisory Role:** Dendreon

**Research Funding:** Amgen (Inst)

#### Kenneth Carson

**Honoraria:** Genentech, Spectrum Pharmaceuticals, Celgene, Millennium Pharmaceuticals

**Consulting or Advisory Role:** Celgene, Spectrum Pharmaceuticals, Millennium Pharmaceuticals, Genentech

**Speakers' Bureau:** Genentech

**Research Funding:** Millennium Pharmaceuticals, Kyowa-Hakko Kirin

**Expert Testimony:** Abbvie

**Travel, Accommodations, Expenses:** Spectrum Pharmaceuticals, Celgene, Genentech

#### Jeffrey Crawford

**Consulting or Advisory Role:** Amgen, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Hospira, Ono Pharmaceutical, Aveo, Merck, Novartis

**Research Funding:** Amgen (Inst), AstraZeneca (Inst), GTx (Inst), MedImmune (Inst), Morphotek (Inst), Clovis (Inst), Fibrogen (Inst)

#### Scott Cross

No relationship to disclose

#### John Goldberg

**Consulting or Advisory Role:** Health Affairs

**Research Funding:** ArQule

**Travel, Accommodations, Expenses:** Roche

#### James Khatcheressian

No relationship to disclose

#### Natasha Leighl

**Research Funding:** Novartis Canada (Inst)

#### Cheryl Perkins

No relationship to disclose

#### George Somlo

**Consulting or Advisory Role:** Pfizer, Genentech, Novartis, Abbvie, Celgene, Quest Diagnostics, NanoString Technologies

**Speakers' Bureau:** Jansen, Millennium Pharmaceuticals

**Research Funding:** Celgene (Inst), Genentech (Inst)

**Other Relationship:** Abbvie (steering committee)

#### James Wade

**Employment:** Johnson & Johnson (I)

**Stock or Other Ownership:** Seattle Genetics, Celgene

#### Antoinette Wozniak

**Honoraria:** Xcenda, Biodesix

**Consulting or Advisory Role:** Genentech/Roche, Boehringer Ingelheim, Novartis, AstraZeneca

**Speakers' Bureau:** Biodesix

**Research Funding:** Astex Therapeutics

#### James O. Armitage

**Leadership:** Tesaro Bio

**Consulting or Advisory Role:** GlaxoSmithKline, Roche, Spectrum Pharmaceuticals, ZIOPHARM Oncology, Conatus IDMC, Celgene

**Acknowledgment**

We thank Supriya Mohile, Mariana Chavez Mac Gregor, Benjamin Djulbegovic, and the Clinical Practice Guidelines Committee for their thoughtful reviews of and insightful comments on this guideline document.

**Appendix****Table A1.** Update Committee Membership

Member	Affiliation/Location
Thomas J. Smith, MD (co-chair)	Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
James O. Armitage, MD (co-chair)	University of Nebraska Medical Center, Omaha, NE
Gary H. Lyman, MD, MPH	Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
Kenneth R. Carson, MD, PhD	Washington University, St Louis, MO
Jeffrey Crawford, MD	Duke Medicine, Durham, NC
Scott J. Cross, MD	Virginia Oncology Associates, Norfolk, VA
John M. Goldberg, MD	University of Miami Miller School of Medicine, Miami, FL
Natasha B. Leighl, MD, MMSc	Princess Margaret Cancer Centre, Toronto, Ontario, Canada
James L. Khatcheressian, MD (PGIN representative)	Virginia Cancer Institute, Richmond, VA
Cheryl L. Perkins, MD (patient representative)	Dallas, TX
George Somlo, MD	City of Hope National Medical Center, Duarte, CA
James L. Wade, MD	Cancer Care Specialists of Central Illinois, Decatur, IL
Antoinette J. Wozniak, MD	Karmanos Cancer Institute, Detroit, MI

NOTE. American Society of Clinical Oncology staff: Kari Bohlke, ScD.  
Abbreviation: PGIN, Practice Guideline Implementation Network.